Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment

被引:1
|
作者
Lemberg, Kathryn M. [1 ,2 ]
Gross, Andrea M. [2 ]
Sproule, Lauren M. [3 ]
Liewehr, David J. [4 ]
Dombi, Eva [2 ]
Baldwin, Andrea [5 ]
Steinberg, Seth M. [4 ]
Bornhorst, Miriam [6 ,7 ]
Lodish, Maya [8 ]
Blakeley, Jaishri O. [9 ]
Widemann, Brigitte C. [2 ]
机构
[1] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA
[3] McGill Univ, Montreal, PQ, Canada
[4] Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD USA
[5] Frederick Natl Lab Canc Res, Clin Res Directorate, Frederick, MD USA
[6] Childrens Natl Hosp, Gilbert Family Neurofibromatosis Inst, Washington, DC USA
[7] Ann & Robert H Lurie Childrens Hosp Chicago, Ctr Canc & Blood Disorders, Chicago, IL USA
[8] Univ Calif San Francisco, Div Pediat Endocrinol, San Francisco, CA USA
[9] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
GROWTH; PUBERTY; ADULTS; FAMILY; AGE;
D O I
10.1038/s41390-024-03474-z
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BACKGROUND: In children and adolescents/young adults (CAYA) with neurofibromatosis type I (NF1), associations between anthropometric measurements, plexiform neurofibroma (pNF) tumor volume (TV), and treatment history are unknown. METHODS: We retrospectively investigated anthropometrics in CAYA on the National Cancer Institute (NCI) NF1 Natural History Study who had pNF TV assessed by imaging (n = 106). We determined CDC height/weight percentiles and estimated Preece-Baines (PB) height growth curve parameters. We evaluated variables that could impact height/weight including: (1) pNF volume, (2) pNF directed therapy, and (3) serum IGF-1. RESULTS: 23% of males and 20% of females had height <5th percentile; 13% of males had weight <5th percentile. Estimated median final adult height for males was 171.6 cm (CDC 23rd percentile) and for females was 156.2 cm (CDC 14th percentile). Inverse associations between height and weight percentiles and pNF volume were observed (Spearman's r = -0.277, -0.216, respectively). Estimated median final height was not meaningfully affected by patients who received pNF-directed treatment with MEK inhibitor. 52% of low serum IGF-1 measurements were concurrent with a height percentile <5th. CONCLUSIONS: Greater than expected percentages of patients had height/weight <5th percentile, and median final adult heights were <CDC 25th percentile. pNF volume was inversely associated with height/weight percentiles.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Miniature Palpebral Plexiform Neurofibroma in Neurofibromatosis Type 2
    Charles, Norman C.
    Kim, Eleanore T.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2023, 39 (06): : E186 - E188
  • [22] Congenital Craniofacial Plexiform Neurofibroma in Neurofibromatosis Type 1
    Cacchione, Antonella
    Carboni, Alessia
    Lodi, Mariachiara
    De Vito, Rita
    Carai, Andrea
    Marrazzo, Antonio
    Macchiaiolo, Marina
    Voicu, Ioan Paul
    Mastronuzzi, Angela
    Colafati, Giovanna Stefania
    DIAGNOSTICS, 2021, 11 (02)
  • [23] Successful utilization of topical trametinib for neurofibromatosis type I-associated plexiform neurofibroma
    Melnikov, Leonid
    Brichta, Lars
    Schloemer, Nathan J.
    PEDIATRIC DERMATOLOGY, 2024, 41 (06) : 1246 - 1247
  • [24] Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1
    Mateos, Maria Elena
    Lopez-Laso, Eduardo
    Vicente, Josefina
    Ortega, Rosa
    Vazquez, Fernando
    Luis Perez-Navero, Juan
    PEDIATRICS INTERNATIONAL, 2020, 62 (07) : 857 - 859
  • [25] Segmental colonic involvement of plexiform neurofibroma in neurofibromatosis type 1
    Yang, KH
    Rhim, H
    Cho, OK
    Ko, BH
    Kim, Y
    Lee, HW
    Hong, EK
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2002, 26 (01) : 129 - 131
  • [26] Extensive Plexiform Neurofibroma Presenting as Clitoromegaly in Neurofibromatosis Type 1
    Nalbantoglu, Ozlem
    Arslan, Gulcin
    Ozkaya, Beyhan
    Genc, Sinan
    Ozkan, Behzat
    IZMIR DR BEHCET UZ COCUK HASTANESI DERGISI, 2021, 11 (02): : 215 - 218
  • [27] Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
    Tian, Zhuowei
    You, Yuanhe
    Xiao, Meng
    Liu, Jialiang
    Xu, Guisong
    Ma, Chunyue
    Du, Zhong
    Wang, Yanan
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2023, 20 (01): : 125 - 135
  • [28] Intestinal mesenteric involvement with plexiform neurofibroma in neurofibromatosis type 1
    Mamoglu, MI
    Çay, A
    Yarïs, N
    Yayla, S
    Sarihan, H
    PEDIATRICS INTERNATIONAL, 2006, 48 (03) : 337 - 339
  • [29] Sphenoid wing dysplasia and plexiform neurofibroma in neurofibromatosis type 1
    Rennert, Robert C.
    Pannell, J. Scott
    Levy, Michael L.
    Khalessi, Alexander A.
    ANZ JOURNAL OF SURGERY, 2018, 88 (7-8) : E615 - E616
  • [30] Plexiform neurofibroma with neurofibromatosis type I/ von Recklinghausen's disease: A rare case report
    Poswal, Pooja
    Bhutani, Namita
    Arora, Sunil
    Kumar, Raj
    ANNALS OF MEDICINE AND SURGERY, 2020, 57 : 346 - 350